# Acthar SLE (Systemic Lupus Erythematosus)

> **NCT02779153** · PHASE4 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Repository Corticotropin Injection

## Interventions

- **DRUG:** Acthar low dose (40 U)
- **DRUG:** Acthar high dose (80 U)

## Key facts

- **NCT ID:** NCT02779153
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** closed in agreement of the sponsor and institution due to lack of patient accrual.
- **Last updated:** 2019-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779153, "Acthar SLE (Systemic Lupus Erythematosus)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02779153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*